Latest Interferon beta-1a Stories
According to a recent study, people who received injections of the multiple sclerosis (MS) drug interferon beta-1a directly after noticing signs of possible MS were less likely to progress into definite MS compared to those who switched to interferon beta-1a from placebo.
People who received injections of the multiple sclerosis (MS) drug interferon beta-1a soon after their first signs of possible MS were less likely to progress to clinically definite MS than people who switched to interferon beta-1a from placebo.
ROCKLAND, Mass., March 2, 2011 - EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a complete response letter (CRL) from the U.S.
ROCKLAND, Mass., Feb. 10, 2011 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced the opening of a state-of-the-art research center in Billerica, MA, establishing it as a "hub" within the Merck KGaA research organization.
NEW YORK, Dec.
EXTON, Pa., Dec. 6, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that surveyed neurologists indicate that their initial trial of Novartis's Gilenya has been hampered by potential safety / tolerability concerns and monitoring requirements.
- A young chicken: also used as a pet name for children.